Program
Anti-mutant Calreticulin Monoclonal Antibody INCA033989
Its studies are mostly in Myeloproliferative Disorders · Thrombocythemia, Essential, led by Incyte.
Drug pageAnti-mutant Calreticulin Monoclonal Antibody INCA033989: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Incyte | 44 open or running | phase 3since May 29, 2026 | Jun 21, 2023 | Feb 29, 2028phase 1 · NCT05936359 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 21, 2023First study: phase 1 study in Myeloproliferative DisordersFirst studyNCT05936359 · 160 enrolled · Australia, Canada, Denmark and more
- Aug 30, 2023Phase 1 study in Myeloproliferative DisordersNCT06034002 · 290 planned · United States
- Feb 26, 2026Phase 1 study in Healthy ParticipantsNCT07448155 · 108 enrolled · United States
- May 29, 2026Phase 3 study in Thrombocythemia, EssentialPhase 3 reachedNCT07623200 · 426 planned · United States, Australia, Austria and more
Ahead
- Nov 14, 2026Primary completion: phase 1 study in Healthy ParticipantsNCT07448155
- Feb 29, 2028Primary completion: phase 1 study in Myeloproliferative DisordersNCT05936359
- Oct 29, 2028Primary completion: phase 1 study in Myeloproliferative DisordersNCT06034002
- Jun 15, 2029Primary completion: phase 3 study in Thrombocythemia, EssentialNCT07623200
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07623200Thrombocythemia, Essential · United States, Australia, Austria and more | 3 | Recruiting | Jun 15, 2029 | 426 |
| NCT07448155Healthy Participants · United States | 1 | Active, not recruiting | Nov 14, 2026 | 108 |
| NCT06034002Myeloproliferative Disorders · United States | 1 | Recruiting | Oct 29, 2028 | 290 |
| NCT05936359Myeloproliferative Disorders · Australia, Canada, Denmark and more | 1 | Active, not recruiting | Feb 29, 2028 | 160 |
How it is read
Names in the registry
- “INCA033989”, 4 entries
Conditions, from the studies’ own filings
- Myeloproliferative Disorders, 2 studies
- Thrombocythemia, Essential, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.